These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27837494)

  • 1. Identification of the Targets of Type III Secretion System Inhibitors.
    Condry DL; Nilles ML
    Methods Mol Biol; 2017; 1531():203-211. PubMed ID: 27837494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Inhibitors of the Type III Secretion System.
    Gu L; Zhou S; Zhu L; Liang C; Chen X
    Molecules; 2015 Sep; 20(9):17659-74. PubMed ID: 26404233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Targets and Strategies for Inhibition of the Bacterial Type III Secretion System (T3SS); Inhibitors Directly Binding to T3SS Components.
    Hotinger JA; Pendergrass HA; May AE
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33669653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type III Secretion-Dependent Sensitivity of Escherichia coli O157 to Specific Ketolides.
    Fernandez-Brando RJ; Yamaguchi N; Tahoun A; McAteer SP; Gillespie T; Wang D; Argyle SA; Palermo MS; Gally DL
    Antimicrob Agents Chemother; 2016 Jan; 60(1):459-70. PubMed ID: 26525795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of chlamydial T3SS inhibitors through virtual screening against T3SS ATPase.
    Grishin AV; Luyksaar SI; Kapotina LN; Kirsanov DD; Zayakin ES; Karyagina AS; Zigangirova NA
    Chem Biol Drug Des; 2018 Mar; 91(3):717-727. PubMed ID: 29068165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic Cyclic Peptomers as Type III Secretion System Inhibitors.
    Lam H; Schwochert J; Lao Y; Lau T; Lloyd C; Luu J; Kooner O; Morgan J; Lokey S; Auerbuch V
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A global survey of bacterial type III secretion systems and their effectors.
    Hu Y; Huang H; Cheng X; Shu X; White AP; Stavrinides J; Köster W; Zhu G; Zhao Z; Wang Y
    Environ Microbiol; 2017 Oct; 19(10):3879-3895. PubMed ID: 28401683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium.
    Kimura K; Iwatsuki M; Nagai T; Matsumoto A; Takahashi Y; Shiomi K; Omura S; Abe A
    J Antibiot (Tokyo); 2011 Feb; 64(2):197-203. PubMed ID: 21139624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Type III Secretion System Secreted Proteins.
    Condry DL; Nilles ML
    Methods Mol Biol; 2017; 1531():93-99. PubMed ID: 27837484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-Directed Mutagenesis and Its Application in Studying the Interactions of T3S Components.
    Francis MS; Amer AA; Milton DL; Costa TR
    Methods Mol Biol; 2017; 1531():11-31. PubMed ID: 27837478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Noncompetitive Type Three Secretion System ATPase Inhibitors Shut Down
    Case HB; Mattock DS; Miller BR; Dickenson NE
    Biochemistry; 2020 Jul; 59(28):2667-2678. PubMed ID: 32567308
    [No Abstract]   [Full Text] [Related]  

  • 12. A Method for Characterizing the Type III Secretion System's Contribution to Pathogenesis: Homologous Recombination to Generate Yersinia pestis Type III Secretion System Mutants.
    Osei-Owusu P; Nilles ML; Bradley DS; Alvine TD
    Methods Mol Biol; 2017; 1531():155-164. PubMed ID: 27837489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PurA is the main target of aurodox, a type III secretion system inhibitor.
    Watanabe Y; Haneda T; Kimishima A; Kuwae A; Suga T; Suzuki T; Iwabuchi Y; Honsho M; Honma S; Iwatsuki M; Matsui H; Hanaki H; Kanoh N; Abe A; Asami Y; Ōmura S
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2322363121. PubMed ID: 38640341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of Type III Secretion System Needle Complexes by Shearing.
    Nilles ML; Condry DL; Osei-Owusu P
    Methods Mol Biol; 2017; 1531():61-70. PubMed ID: 27837481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The type III secretion system needle, tip, and translocon.
    Dey S; Chakravarty A; Guha Biswas P; De Guzman RN
    Protein Sci; 2019 Sep; 28(9):1582-1593. PubMed ID: 31301256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Type Three Secretion System in Pseudomonas aeruginosa.
    Anantharajah A; Mingeot-Leclercq MP; Van Bambeke F
    Trends Pharmacol Sci; 2016 Sep; 37(9):734-749. PubMed ID: 27344210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Transcriptional Control to Increase Secretion of Heterologous Proteins in T3S Systems.
    Metcalf KJ; Tullman-Ercek D
    Methods Mol Biol; 2017; 1531():71-79. PubMed ID: 27837482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vfr Directly Activates exsA Transcription To Regulate Expression of the Pseudomonas aeruginosa Type III Secretion System.
    Marsden AE; Intile PJ; Schulmeyer KH; Simmons-Patterson ER; Urbanowski ML; Wolfgang MC; Yahr TL
    J Bacteriol; 2016 May; 198(9):1442-50. PubMed ID: 26929300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors.
    Moir DT; Opperman TJ; Aron ZD; Bowlin TL
    Drug Discov Today; 2021 Sep; 26(9):2173-2181. PubMed ID: 33845218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blue Native Protein Electrophoresis to Study the T3S System Using Yersinia pestis as a Model.
    Henderson TA; Nilles ML
    Methods Mol Biol; 2017; 1531():33-46. PubMed ID: 27837479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.